08:22 AM EST, 11/07/2025 (MT Newswires) -- Eli Lilly's ( LLY ) injectable diabetes treatment Mounjaro has become the top-selling drug in India, surpassing GSK's (GSK) antibiotic Augmentin, Reuters reported Friday, citing data from research firm Pharmarack.

Mounjaro, also used as a weight-loss therapy, registered sales of 1 billion rupees ($11.3 million) in October against Augmentin sales of 800 million rupees for the month, according to the report.

Augmentin had 5.8 million units sold in October, compared with 85,000 units for Mounjaro, which is priced much higher, the report said.

Lilly did not immediately reply to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)